ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

HHS Task Force Says NCI Drug Program Effective, Otters Suggestions; DeVita Responds

March 26, 1982

First Mobil NMR Scanner Goes Into Operation At Temple

June 22, 1984

Columbia To Host U.S.- China Conference

February 15, 1980

NCCN’s First Physician CEO: Robert Carlson Pledges Broader Research and Policy Agenda

October 5, 2012

In Brief: Senate Subcommittee Vote: $950 Million Plus training DeVita Needs New Clinical Assistant

July 21, 1978

Rapid Non-Invasive Imaging Of Biochemical Composition In Breast Tumor Margins

April 24, 2009